Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 -VEGFR Hb0025 (Anti-PD-L1 & VEGF)
For research use only. Not for use in humans.

Hb0025 (Anti-PD-L1 & VEGF)

Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.

Hb0025 (Anti-PD-L1 & VEGF)

Quality Control

Batch: A401101 Purity: 99% Protein concentration: Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.

Product Details

CAS No. N/A
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07383116 NOT_YET_RECRUITING Drug: Pemetrexed injection|Drug: Carboplatin Injection|Drug: Non Squamous Non-small Cell Lung Cancer Shanghai Huaota Biopharmaceutical Co., Ltd. 2026-01-15 PHASE3
NCT07360132 NOT_YET_RECRUITING Drug: Carboplatin Injection|Drug: Paclitaxel Injection Squamous Non-small Cell Lung Cancer Shanghai Huaota Biopharmaceutical Co., Ltd. 2026-01-15 PHASE3
NCT07376629 ENROLLING_BY_INVITATION Drug: HB0025 20 mg/kg plus nab-paclitaxel|Drug: HB0025 10 mg TNBC Huabo Biopharm Co., Ltd. 2025-08-14 PHASE2
NCT06758557 RECRUITING Drug: HB0025|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carbopl Advanced NSCLC; Advanced Endometrial Cancer Huabo Biopharm Co., Ltd. 2024-01-31 PHASE1; PHASE2
NCT06222125 UNKNOWN Drug: HB0025 Renal Cancer Huabo Biopharm Co., Ltd. 2023-01-30 PHASE2
NCT05756972 ACTIVE_NOT_RECRUITING Drug: PM8002|Drug: Carboplatin|Drug: Pemetrexed NSCLC Biotheus Inc. 2023-06-26 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-02-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.